Unexpectedly low rates of neuropsychiatric adverse effects associated with mefloquine repurposed for the treatment of glioblastoma

Cancer. 2019 Apr 15;125(8):1384-1385. doi: 10.1002/cncr.31961. Epub 2019 Feb 1.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Glioblastoma*
  • Humans
  • Mefloquine
  • Memantine
  • Metformin*
  • Temozolomide

Substances

  • Metformin
  • Mefloquine
  • Memantine
  • Temozolomide